Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapaquistat Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 known ✓ | P37268 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapaquistat Acetate SCHEMBL12882274 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL29395209 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL206424 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| Lapaquistat Acetate SCHEMBL29379346 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL14377991 | 0.99 | FDFT1 (0.99) | FDFT1 | |
| SCHEMBL14377992 | 0.97 | FDFT1 (0.95) | FDFT1 | |
| SCHEMBL14161201 | 0.95 | FDFT1 (0.90) | FDFT1 | |
| SCHEMBL4103967 | 0.95 | FDFT1 (0.90) | FDFT1 | |
| SCHEMBL7239462 | 0.94 | FDFT1 (0.89) | FDFT1 | |
| SCHEMBL4113577 | 0.94 | FDFT1 (0.88) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2203415-B1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-20130231388-A1 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT | SANOFI (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20130231388-A1 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT | SANOFI (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2252591-B1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010000353-A1 | SULFONAMIDES WITH HETEROCYCLE AND OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009149819-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009039942-A1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008052658-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231388-A1 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT | PPOX, OAT, NOTUM | FDFT1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.